Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

Gracell Biotechnologies Inc.

Gracell is developing cell therapy that delivers fast, deep and durable responses for cancer and autoimmune disease patients. The company is focused on discovering and developing innovative and highly efficacious cell therapies to address major industry challenges and fulfill unmet medical needs, self-described as aiming to disrupt conventional approaches to CAR-T cell therapies.

	Dec '19	Dec '20	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23
net income	-42.80M -	-83.59M 95.29%	-25.09M 69.99%	-18.37M 26.79%	-22.18M 20.75%	-20.93M 5.62%	-9.33M 55.42%
depreciation and amortization	1.32M -	9.35M 606.19%
deferred income tax
stock based compensation
change in working capital	9.13M -	9.61M 5.31%
accounts receivables
inventory
accounts payables
other working capital
other non cash items	-429K -	677K 257.81%	25.09M 3,605.59%	18.37M 26.79%	22.18M 20.75%	20.93M 5.62%	9.33M 55.42%
net cash provided by operating activities	-32.78M -	-63.95M 95.08%
investments in property plant and equipment	-10.24M -	-14.11M 37.78%
acquisitions net
purchases of investments	-71.12M -	45.65M 164.18%
sales maturities of investments	80M -	-43.69M 154.61%
other investing activites
net cash used for investing activites	-1.36M -	-12.15M 793.46%
debt repayment		-122K -
common stock issued
common stock repurchased
dividends paid
other financing activites		693.25M -
net cash used provided by financing activities		693.13M -
effect of forex changes on cash	-3.77M -	-19.50M 416.72%
net change in cash	-37.92M -	597.53M 1,675.92%	-27.45M 104.59%	7.39M 126.90%	-23.90M 423.61%	-22.29M 6.72%	66.60M 398.72%
cash at beginning of period	349.97M -	156.78M 55.20%	229.32M 46.27%	201.86M 11.97%	209.25M 3.66%	185.35M 11.42%	163.05M 12.03%
cash at end of period	312.06M -	754.31M 141.72%	201.86M 73.24%	209.25M 3.66%	185.35M 11.42%	163.05M 12.03%	229.65M 40.84%
operating cash flow	-32.78M -	-63.95M 95.08%
capital expenditure	-10.24M -	-14.11M 37.78%
free cash flow	-43.02M -	-78.06M 81.44%

NASDAQ:GRCL

Gracell

Last Close

10.24

21/02 21:00

Market Cap

989.87M

Beta: −1.83

Volume Today

6.37M

Avg: 131.30K

PE Ratio

−12.25

PFCF: -

Preview